Intensive Blood Pressure and LDL Lowering in Diabetic Patients With Coronary Artery Disease
Intensive Blood Pressure and LDL Lowering for Better Survival and Cardiovascular Outcome in Diabetic Patients With Coronary Artery Disease: Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Saga, Japan, 849-8501
- Saga University Hospital
-
-
Okinawa
-
Nishihara, Okinawa, Japan, 903-0215
- University Hospital, University of the Ryukyus
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Type 2 diabetic patients with coronary artery disease and history of acute coronary syndrome
- Patients whose blood pressure and LDL cholesterol levels are above values recommended by the current guideline
Exclusion Criteria:
- Patients who have active malignant tumor
- Patients who are on hemodialysis due to end stage kidney disease
- Patients whom statins are contraindicated
- Patients who had acute coronary syndrome or stroke within 3 months
- Patients who are pregnant or on breast feeding
- Patients whose physicians deem that attending this trial is contraindicated or inappropriate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: intensive control
systolic blood pressure less than 120mmHg and LDL cholesterol within 70- 85mg/dl
|
use any medication to achieve systolic blood pressure less than 120mmHg and LDL cholesterol within 70-85mg/dl
|
|
Active Comparator: standard control
systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
|
use any medication to achieve systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
composite endpoint
Time Frame: 3 years
|
composite endpoint consisting of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke and unstable angina requiring hospital administration
|
3 years
|
|
important secondary composite endpoint
Time Frame: 3 years
|
composite endpoint consisting of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, unstable angina requiring hospital administration, and admission for heart failure
|
3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
all-cause mortality
Time Frame: 3 years
|
death due to any cause
|
3 years
|
|
myocardial infarction
Time Frame: 3 years
|
non fatal myocardial infarction
|
3 years
|
|
stroke
Time Frame: 3 years
|
non fatal stroke excluding transient ischemic attack
|
3 years
|
|
Cardiovascular death
Time Frame: 3 years
|
Cardiovascular death
|
3 years
|
|
end stage renal disease
Time Frame: 3 years
|
end stage renal disease needs kidney transplantation or hemodialysis
|
3 years
|
|
peripheral artery disease
Time Frame: 3 years
|
peripheral artery disease
|
3 years
|
|
new onset or deterioration of heart failure
Time Frame: 3 years
|
new onset or deterioration of heart failure
|
3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Shinichiro Ueda, MD, PhD, Professor of Clinical Pharmacology and Therapeutics, University of the Ryukyus
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Lipid Metabolism Disorders
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Hypertension
- Diabetes Mellitus, Type 2
- Dyslipidemias
Other Study ID Numbers
Other Study ID Numbers
- H21-rinsho shiken ippan-017
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.